A
Abigail I. Wald
Researcher at University of Pittsburgh
Publications - 44
Citations - 1833
Abigail I. Wald is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 16, co-authored 29 publications receiving 1348 citations.
Papers
More filters
Journal ArticleDOI
Targeted Next-Generation Sequencing Panel (ThyroSeq) for Detection of Mutations in Thyroid Cancer
TL;DR: The ThyroSeq NGS panel allows simultaneous testing for multiple mutations with high accuracy and sensitivity, requires a small amount of DNA and can be performed in a variety of thyroid tissue and fine-needle aspiration samples, and provides quantitative assessment of mutant alleles.
Journal ArticleDOI
Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia.
Aatur D. Singhi,Kevin McGrath,Randall E. Brand,Asif Khalid,Herbert J. Zeh,Jennifer Chennat,Kenneth E. Fasanella,Georgios I. Papachristou,Adam Slivka,David L. Bartlett,Anil K. Dasyam,Melissa E. Hogg,Kenneth K. Lee,James W. Marsh,Sara E. Monaco,N. Paul Ohori,James F. Pingpank,Allan Tsung,Amer H. Zureikat,Abigail I. Wald,Marina N. Nikiforova +20 more
TL;DR: Preoperative NGS of PCF for KRAS/GNAS mutations is highly sensitive for IPMNs and specific for mucinous PCs, and the combination of TP53/PIK3CA/PTEN alterations is a useful preoperative marker for advanced neoplasia.
Journal ArticleDOI
Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules.
Marina N. Nikiforova,Stephanie Mercurio,Abigail I. Wald,Michelle Barbi de Moura,Keith M. Callenberg,Lucas Santana-Santos,William E. Gooding,Linwah Yip,Robert L. Ferris,Yuri E. Nikiforov +9 more
TL;DR: This study evaluated the analytical performance of the newly created ThyroSeq v3 test and concluded that the test has clinical utility for thyroid nodules with indeterminate fine‐needle aspiration (FNA) cytology.
Journal ArticleDOI
ALTERATION OF microRNA PROFILES IN SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK CELL LINES BY HUMAN PAPILLOMAVIRUS
TL;DR: Human papillomavirus‐positive cases of squamous cell carcinoma of the head and neck (SCCHN) have a much better disease outcome compared to SCCHN cases lacking HPV, and differences in microRNA (miRNA) expression may affect their clinical outcomes.
Journal ArticleDOI
Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors
Marina N. Nikiforova,Abigail I. Wald,Melissa A. Melan,Somak Roy,Shan Zhong,Ronald L. Hamilton,Frank S. Lieberman,Jan Drappatz,Nduka Amankulor,Ian F. Pollack,Yuri E. Nikiforov,Craig Horbinski +11 more
TL;DR: An amplification-based targeted NGS assay that analyzes 30 genes for single nucleotide variants and indels, 24 genes for copy number variations (CNVs), and 14 types of structural alterations in BRAF, EGFR, and FGFR3 genes in a single workflow that allows rapid and cost-effective profiling of brain tumor specimens and thus provides valuable information for patient management.